Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 6Sarcoma, Ewing 2Osteosarcoma 2Neuroectodermal Tumors, Primitive 2Medulloblastoma 2Glioma 2Glioblastoma 2Astrocytoma 2Typical Teratoid Rhabdoid Tumor 1Rhabdoid Tumor 1Prostatic Neoplasms 1Osteosarcoma Recurrent 1Oligodendroglioma 1Non-melanoma Skin Cancer 1Melanoma 1Lymphoma, Follicular 1Lung Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 8X-Rays 7Phantoms, Imaging 7Cyclophosphamide 7Specimen Handling 6Nuclear Medicine Department, Hospital 5fludarabine 4Etoposide 4Biopsy 4tazemetostat 3etoposide phosphate 3Vincristine 3Temozolomide 3Nivolumab 3Cisplatin 3Carboplatin 3Automobiles 3ulixertinib 2tipifarnib 2selpercatinib 2palbociclib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2Topotecan 2Sirolimus 2Methotrexate 2Mesna 2LY3023414 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdoid Tumor × Eflornithine × 1 year × Clear all
NCT06465199 2026-06-03

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
289 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡